Market Place
Sourcing Support
IPAB stays revocation of Pharmacyclics’ patent on anti-cancer drug Ibrutinib
23 Jun 2020 //
PHARMABIZ
Patent for Pharmacyclic`s cancer drug revoked on challenge by Laurus Labs
23 Mar 2020 //
BUSINESS-STANDARD
Swiss biotech ADC Therapeutics guns for $150M IPO
09 Sep 2019 //
FIERCEBIOTECH
Pharma shells out $3B to doctors and hospitals—with Roche, Sanofi leading: CMS
02 Jul 2019 //
FIERCE PHARMA
AstraZeneca`s Calquence treads on Imbruvica`s turf with second phase 3 CLL win
07 Jun 2019 //
FIERCE PHARMA
AbbVie unveils Venclexta data
04 Jun 2019 //
FIERCE PHARMA
Ascentage Pharma Appoints Jeff Kmetz as Chief Business Officer
15 Feb 2019 //
PR NEWSWIRE
Imbruvica® (Ibrutinib) : Janssen Biotech vs. Zydus, Cadila Healthcare
29 Jan 2019 //
PATENT LITIGATION
Cerdelga (eliglustat) : Genzyme vs. Cipla Ltd.
24 Nov 2018 //
PATENT LITIGATION
Imbruvica (ibrutinib): Pharmacyclics, Janssen Biotech vs. Hetero Labs
24 Nov 2018 //
PATENT LITIGATION
Lexiscan (regadenoson) : Astellas Pharma, Gilead Sciences vs. Sun Pharma
01 Nov 2018 //
PATENT LITIGATION
Would AbbVie’s top execs pull the trigger on a $30B M&A deal?
31 Jul 2018 //
ENDPTS
Xynomic preps broad push for HDAC cancer drug
01 Jun 2018 //
FIERCE BIOTECH
AbbVie to keep cheaper Imbruvica formula on the market
17 May 2018 //
FIERCE PHARMA
Imbruvica®( Ibrutinib) : Acerta Pharma v. Pharmacyclics
18 Apr 2018 //
PATENT LITIGATION
Imbruvica® (Ibrutinib) : Pharmacyclics v. Zydus Worldwide DMCC
16 Feb 2018 //
PATENT LITIGATION
Imbruvica® (Ibrutinib): Pharmacyclics v. Cipla Limited
12 Feb 2018 //
PATENT LITIGATION
Novartis sees gaps in cancer pipeline but is adamant it doesn’t need an I-O deal
01 Jun 2017 //
FIERCE BIOTECH
AbbVie pens oncology research pacts with academic teams
06 Dec 2016 //
FIERCE BIOTECH
Reata Pharmaceuticals, Appoints Dawn Carter Bir as VP and CCO
11 Oct 2016 //
GLOBENEWSWIRE
Medivation’s Drug for Stubborn Cancers Raises Acquirer Allure
02 Jun 2016 //
BLOOMBERG
AbbVie chief secures his spot on biopharma`s highest-paid list with $20M
11 Mar 2016 //
FIERCE PHARMA
UK cost agency rejects leukaemia drug from J&J and AbbVie
02 Mar 2016 //
REUTERS
Boehringer, AbbVie Said to Be in Cancer-Partnership Talks
01 Mar 2016 //
BLOOMBERG
AbbVie CEO Argues Value of Company’s Pipeline, Piques Analysts Interest
20 Jan 2016 //
BIOSPACE
Health Care`s $605 Billion Buying Binge May Slow in 2016
06 Jan 2016 //
BLOOMBERG
Threshold Pharmaceuticals to reduce workforce
21 Dec 2015 //
THE MOTLEY FOOL
Genentech Touts Hematology Data for Gazyva and Venetoclax in CLL
16 Dec 2015 //
BIOSPACE
Did AbbVie make a smart $21 billion bet?
10 Dec 2015 //
CHICAGO BUSINESS
AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA
14 Nov 2015 //
PR NEWS WIRE
Bad news for AbbVie: Humira copies expected to rack up biggest biosim sales
17 Jun 2015 //
FIERCE PHARMA
AbbVie (ABBV) Announces Offer Consideration For Acquisition Of Pharmacyclics (PCYC)
22 May 2015 //
BIOSPACE
The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D
18 May 2015 //
FIERCE BIOTECH
Baxter pads biopharma unit with pre-spinoff oncology buy
13 May 2015 //
FIERCE PHARMA MARKETING
UPDATED: Alexion scoops up a rare-disease blockbuster in $8.4B Synageva buyout
07 May 2015 //
FIERCE BIOTECH
Drugmakers to Congress: You want patent reforms? Stop pharma challenger Bass
05 May 2015 //
FIERCE PHARMA
How Lead Product Dependency Shapes Corporate Strategy In Pharma
28 Apr 2015 //
FORBES
UPDATED: Hedge funder Kyle Bass` latest patent targets? Imbruvica and Pharmacyclics
22 Apr 2015 //
FIERCE PHARMA
Careful, European drugmakers. Fitch says M&A may be a bit too heated
17 Apr 2015 //
FIERCE PHARMA
Novartis has fresh data to support newly acquired CLL drug Arzerra
15 Apr 2015 //
FIERCE PHARMA
Could a restructuring help protect AbbVie when revenue troubles hit?
15 Apr 2015 //
FIERCE PHARMA
35 Global Biotech Firm Contributed 26.5 Bn Revenue in 2014
09 Apr 2015 //
BIOSPECTRUM ASIA
UPDATE 1-Pharmacyclics Cancer Drug Successful As Combination Therapy - Independent Panel
18 Mar 2015 //
REUTERS
The Hottest Question in Pharma: Which Company Will Be Next To Sell?
18 Mar 2015 //
PHARMALOT
The $42 Billion Drug? Why AbbVie May Have Overpaid for Pharmacyclics
07 Mar 2015 //
PHARMALOT
Abbvie in $21bn Swoop on Pharmacyclics
05 Mar 2015 //
FINANCIAL TIMES
